Its reported link to heart failure, myocardial infarction, and ventricular arrhythmias, wherein elevated levels of galectin-3 correlate with adverse cardiac remodeling and reduced ejection fraction [35,36,37,38,39,40], makes it a potential biomarker for cardiac risk stratification. This evidence concerns the gene LGALS3 and heart failure.